Posted by Michael Wonder on 03 Nov 2021
NICE releases guidance on medicine for patients with thyroid cancer
3 November 2021 - Selpercatinib is used to treat patients with advanced RET fusion positive thyroid cancer.
Selpercatinib is recommended for use within the Cancer Drugs Fund, as an option for treating:
- Advanced RET fusion positive thyroid cancer in adults who need systemic therapy after sorafenib or lenvatinib
- Advanced RET mutant medullary thyroid cancer in people 12 years and older who need systemic therapy after cabozantinib or vandetanib.
